Lung Injury Global Clinical Trials Review, H1, 2013 4/30/2013 \| published by: GlobalData ... information and data relating to the clinical trials on Lung Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook ... \| read more...	$2,500.00
Obstructive Pulmonary Disease Global Clinical Trials Review, H1, 2013 4/30/2013 \| published by: GlobalData ... report provides elemental information and data relating to the clinical trials on Obstructive Pulmonary Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across ... \| read more...	$2,500.00
Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2013 4/30/2013 \| published by: GlobalData ... trial scenario. This report provides elemental information and data relating to the clinical trials on Viral Respiratory Tract Infection. It includes an overview of the trial numbers and their recruitment status as per the site ... \| read more...	$2,500.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - Italy Drug Forecast and Market Analysis to 2022 4/30/2013 \| published by: GlobalData ... to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ... \| read more...	$4,995.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - Germany Drug Forecast and Market Analysis to 2022 4/30/2013 \| published by: GlobalData ... to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ... \| read more...	$4,995.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan Drug Forecast and Market Analysis to 2022 4/30/2013 \| published by: GlobalData ... to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ... \| read more...	$4,995.00
ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment 4/30/2013 \| published by: GBI Research ... to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment”. The report provides insights into the up-and-coming trends of the ADHD market in seven major markets: the US, the ... \| read more...	$3,500.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - Spain Drug Forecast and Market Analysis to 2022 4/30/2013 \| published by: GlobalData ... to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ... \| read more...	$4,995.00
Metastatic Hepatocellular Carcinoma (HCC) – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... on the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Hepatocellular Carcinoma ... \| read more...	$2,000.00
Cardiac Fibrosis – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... for Cardiac Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiac Fibrosis. Cardiac Fibrosis - Pipeline Review, Half Year ... \| read more...	$2,000.00
OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) - Opportunity Analysis and Forecasts to 2017 4/30/2013 \| published by: GlobalData ... in older adults’ =50 years old, with an abysmal prognosis (3-5 years following diagnosis). After decades of being an underserved therapeutic arena, the IPF treatment landscape is set to dramatically change with the anticipated approval ... \| read more...	$5,995.00
MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - EU Analysis and Market Forecasts 4/30/2013 \| published by: GlobalData ... market remains of high interest due to advancements in assay sensitivity both on laboratory and point-of-care platforms. GlobalData expects these advancements to have an impact on other diagnostic tests such as creatine kinase-MB isoenzyme and ... \| read more...	$4,450.00
MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 4/30/2013 \| published by: GlobalData ... of high interest due to advancements in assay sensitivity both on laboratory and point-of-care platforms. GlobalData expects these advancements to have an impact on other diagnostic tests such as creatine kinase-MB isoenzyme and myoglobin. Furthermore, ... \| read more...	$4,450.00
OpportunityAnalyzer: Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017 4/30/2013 \| published by: GlobalData ... to life-threatening lung infections; and obstructs pancreatic enzyme secretions that are essential for the body to break down and absorb nutrients. CF patients have a limited number of available treatment options and significant unmet needs ... \| read more...	$5,995.00
Disruptive Behavior Disorder – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... therapeutic development for Disruptive Behavior Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Disruptive Behavior Disorder. Disruptive Behavior Disorder ... \| read more...	$2,000.00
Motor Neurone Diseases – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... therapeutic development for Motor Neurone Diseases, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Motor Neurone Diseases. Motor Neurone Diseases ... \| read more...	$2,000.00
Skin Ulcers – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... for Skin Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Ulcers. Skin Ulcers - Pipeline Review, Half Year ... \| read more...	$2,000.00
Influenza B Infections – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... therapeutic development for Influenza B Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Influenza B Infections. Influenza B Infections ... \| read more...	$2,000.00
House Dust Mite Allergy – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... on the therapeutic development for House Dust Mite Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for House Dust Mite ... \| read more...	$2,000.00
Oropharyngeal Cancer – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... for Oropharyngeal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oropharyngeal Cancer. Oropharyngeal Cancer - Pipeline Review, Half Year ... \| read more...	$2,000.00
Pulmonary Tuberculosis – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... for Pulmonary Tuberculosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Tuberculosis. Pulmonary Tuberculosis - Pipeline Review, Half Year ... \| read more...	$2,000.00
Streptococcus Pneumoniae Infection – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... therapeutic development for Streptococcus Pneumoniae Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Streptococcus Pneumoniae Infection. Streptococcus Pneumoniae Infection ... \| read more...	$2,000.00
Metastatic Ovarian Cancer – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... therapeutic development for Metastatic Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer. Metastatic Ovarian Cancer ... \| read more...	$2,000.00
Tension -Type Headache Global Clinical Trials Review, H1, 2013 4/30/2013 \| published by: GlobalData ... report provides elemental information and data relating to the clinical trials on Tension -Type Headache. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across ... \| read more...	$2,500.00
PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players 4/30/2013 \| published by: GlobalData ... a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing RSV Market. The report identifies and analyses the key companies shaping and driving the global RSV market. The report ... \| read more...	$2,995.00

< prev 6 7 8 9 10 11 12 13 14 15 next >